Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 243

1.

Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasonic follow-up.

Rensing BJ, Vos J, Smits PC, Foley DP, van den Brand MJ, van der Giessen WJ, de Feijter PJ, Serruys PW.

Eur Heart J. 2001 Nov;22(22):2125-30.

PMID:
11686669
2.

Randomized double-blind comparison of sirolimus-eluting stent versus bare-metal stent implantation in diseased saphenous vein grafts: six-month angiographic, intravascular ultrasound, and clinical follow-up of the RRISC Trial.

Vermeersch P, Agostoni P, Verheye S, Van den Heuvel P, Convens C, Bruining N, Van den Branden F, Van Langenhove G.

J Am Coll Cardiol. 2006 Dec 19;48(12):2423-31. Epub 2006 Nov 28.

3.

Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up.

Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW.

Circulation. 2001 Oct 23;104(17):2007-11.

4.

Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries.

Ge J, Qian J, Wang X, Wang Q, Yan W, Yan Y, Fan B, Ge L, Liu X.

Catheter Cardiovasc Interv. 2007 Feb 1;69(2):198-202.

PMID:
17195205
5.

The sirolimus coated stent: will the Achilles heel of interventional cardiology finally be cured?

Beyar R, Roguin A.

Eur Heart J. 2001 Nov;22(22):2054-7. No abstract available.

PMID:
11686663
6.

Persistent inhibition of neointimal hyperplasia after sirolimus-eluting stent implantation: long-term (up to 2 years) clinical, angiographic, and intravascular ultrasound follow-up.

Degertekin M, Serruys PW, Foley DP, Tanabe K, Regar E, Vos J, Smits PC, van der Giessen WJ, van den Brand M, de Feyter P, Popma JJ.

Circulation. 2002 Sep 24;106(13):1610-3.

7.

Angiographic and intravascular ultrasound study of the effects of overlapping sirolimus- and paclitaxel-eluting stents: comparison with same drug-eluting overlapping stents.

Kang WC, Oh KJ, Han SH, Ahn TH, Chung WJ, Shin MS, Koh KK, Choi IS, Shin EK.

Int J Cardiol. 2007 Dec 15;123(1):12-7. Epub 2007 Feb 6.

PMID:
17289176
8.

No delayed restenosis at 18 months after implantation of sirolimus-eluting stent.

Tanabe K, Degertekin M, Regar E, Ligthart JM, van der Giessen WJ, Serruys PW.

Catheter Cardiovasc Interv. 2002 Sep;57(1):65-8.

PMID:
12203931
9.

Comparison of the efficacy of direct coronary stenting with sirolimus-eluting stents versus stenting with predilation by intravascular ultrasound imaging (from the DIRECT trial).

Hirohata A, Morino Y, Ako J, Sakurai R, Buchbinder M, Caputo RP, Karas SP, Mishkel GJ, Mooney MR, O'shaughnessy CD, Raizner AE, Wilensky RL, Williams DO, Wong SC, Yock PG, Honda Y, Moses JW, Fitzgerald PJ; DIRECT Investigators.

Am J Cardiol. 2006 Dec 1;98(11):1464-7. Epub 2006 Oct 12.

PMID:
17126651
10.

Outcome of percutaneous hybrid coronary revascularization: bare metal stents jeopardize the benefit of sirolimus-eluting stents in the real world.

Fineschi M, Gori T, Pierli C, Casini S, Sinicropi G, Buti A, Del Pasqua A, Bravi A.

Can J Cardiol. 2005 Dec;21(14):1281-5.

PMID:
16341297
11.

Oral rapamycin to prevent human coronary stent restenosis: a pilot study.

Guarda E, Marchant E, Fajuri A, Martínez A, Morán S, Mendez M, Uriarte P, Valenzuela E, Lazen R.

Am Heart J. 2004 Aug;148(2):e9.

PMID:
15309012
12.

Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents.

Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW, Sousa AG.

Circulation. 2005 May 10;111(18):2326-9. Epub 2005 Apr 25.

14.

Success rate of implantation and mid-term outcomes of the sirolimus-eluting stent.

Suzuki S, Kamihata H, Hata T, Hayashi F, Miura A, Yoshinaga M, Karakawa M, Kitaura Y.

Circ J. 2007 Jan;71(1):15-9.

15.

Long-term follow up of diabetic patients treated with sirolimus-eluting stents. An angiographic and three-dimensional intravascular ultrasound study.

Vaz VD, Abizaid A, Chaves A, Feres F, Ferreira E, Mattos L, Staico R, Abizaid A, Tanajura L, Centemero M, Mintz G, Sousa A, Sousa JE.

J Invasive Cardiol. 2006 Apr;18(4):142-6.

PMID:
16729398
16.

Drug-eluting stents.

García-García HM, Vaina S, Tsuchida K, Serruys PW.

Arch Cardiol Mex. 2006 Jul-Sep;76(3):297-319. Review.

PMID:
17091802
17.

Coronary restenosis after sirolimus-eluting stent implantation: morphological description and mechanistic analysis from a consecutive series of cases.

Lemos PA, Saia F, Ligthart JM, Arampatzis CA, Sianos G, Tanabe K, Hoye A, Degertekin M, Daemen J, McFadden E, Hofma S, Smits PC, de Feyter P, van der Giessen WJ, van Domburg RT, Serruys PW.

Circulation. 2003 Jul 22;108(3):257-60. Epub 2003 Jul 14.

18.

Perspectives of drug-eluting stents: the next revolution.

Moses JW, Kipshidze N, Leon MB.

Am J Cardiovasc Drugs. 2002;2(3):163-72. Review.

PMID:
14727979
19.

Coronary in-stent restenosis in diabetic patients after implantation of sirolimus or paclitaxel drug-eluting coronary stents.

Kitoga M, Pasquet A, Preumont V, Kefer J, Hermans MP, Vanoverschelde JL, Buysschaert M.

Diabetes Metab. 2008 Feb;34(1):62-7.

PMID:
18069029
20.

A randomized comparison of sirolimus-eluting stent with balloon angioplasty in patients with in-stent restenosis: results of the Restenosis Intrastent: Balloon Angioplasty Versus Elective Sirolimus-Eluting Stenting (RIBS-II) trial.

Alfonso F, Pérez-Vizcayno MJ, Hernandez R, Bethencourt A, Martí V, López-Mínguez JR, Angel J, Mantilla R, Morís C, Cequier A, Sabaté M, Escaned J, Moreno R, Bañuelos C, Suárez A, Macaya C; RIBS-II Investigators.

J Am Coll Cardiol. 2006 Jun 6;47(11):2152-60.

Supplemental Content

Support Center